Nuvation Bio Inc.

NYSE:NUVB

2.88 (USD) • At close April 15, 2024
Bedrijfsnaam Nuvation Bio Inc.
Symbool NUVB
Munteenheid USD
Prijs 2.88
Beurswaarde 627,972,480
Dividendpercentage 0%
52-weken bereik 0.95 - 4.16
Industrie Biotechnology
Sector Healthcare
CEO Dr. David T. Hung M.D.
Website https://www.nuvationbio.com

An error occurred while fetching data.

Over Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins

Vergelijkbare Aandelen

Invitae Corporation logo

Invitae Corporation

NVTA

0.019 USD

Artivion, Inc. logo

Artivion, Inc.

AORT

20.35 USD

Community Health Systems, Inc. logo

Community Health Systems, Inc.

CYH

3 USD

American Well Corporation logo

American Well Corporation

AMWL

0.557 USD

Phreesia, Inc. logo

Phreesia, Inc.

PHR

22.75 USD

Butterfly Network, Inc. logo

Butterfly Network, Inc.

BFLY

0.937 USD

ADC Therapeutics SA logo

ADC Therapeutics SA

ADCT

4.37 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)